Research map: Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer

Back to the article

Papers in this map

  1. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline · Larissa A. Korde · 2021 · 1058 citations · Cited by this paper
  2. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort · 2026 · Related
  3. Axillary Nodal Evaluation in Breast Cancer: State of the Art · Jung Min Chang · 2020 · 399 citations · Cited by this paper
  4. Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · 2026 · Related
  5. Cancer associated fibroblasts in cancer development and therapy · Hongyuan Jia · 2025 · 217 citations · Cited by this paper
  6. Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer · 2026 · Related
  7. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial · Henry M. Kuerer · 2022 · 166 citations · Cited by this paper
  8. From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · 2026 · Related
  9. Breast MRI for Evaluation of Response to Neoadjuvant Therapy · Beatriu Reig · 2021 · 127 citations · Cited by this paper
  10. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · 2026 · Related
  11. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP · Jennifer Keating Litton · 2023 · 116 citations · Cited by this paper
  12. CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · 2026 · Related
  13. Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives · Valeria Romeo · 2021 · 110 citations · Cited by this paper
  14. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · 2026 · Related
  15. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial · José Manuel Pérez-García · 2024 · 103 citations · Cited by this paper
  16. 68 Ga-FAPI PET/CT as an Alternative to 18 F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma · Ertan Şahin · 2024 · 64 citations · Cited by this paper
  17. Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis · Hye Min Kim · 2015 · 60 citations · Cited by this paper
  18. Initial Results of 68 Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer · Philipp Backhaus · 2022 · 44 citations · Cited by this paper
  19. 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study · Ling Chen · 2023 · 35 citations · Cited by this paper
  20. Beyond N Staging in Breast Cancer: Importance of MRI and Ultrasound-based Imaging · Valerio Di Paola · 2022 · 32 citations · Cited by this paper
  21. Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities · Hyunwoo Lee · 2025 · 30 citations · Cited by this paper
  22. Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer · Wuzhen Chen · 2025 · 27 citations · Cited by this paper
  23. Applications of FAPI PET/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review · Tengfei Li · 2024 · 23 citations · Cited by this paper
  24. Optimal [ 18 F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial · Géraldine Gebhart · 2024 · 18 citations · Cited by this paper
  25. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial · Rosa Di Micco · 2025 · 17 citations · Cited by this paper
  26. FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management · Wei Guo · 2025 · 15 citations · Cited by this paper
  27. 18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis · Yilin Wu · 2024 · 12 citations · Cited by this paper
  28. The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer · Shan Zheng · 2025 · 7 citations · Cited by this paper
  29. The clinical value of FAPI PET/CT in delineating target volumes for nasopharyngeal carcinoma · Wansu Xu · 2025 · 6 citations · Cited by this paper
  30. Pre-operative MRI in evaluating pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer: a study focused on influencing factors of baseline clinical-pathological and imaging features · Qilan Hu · 2024 · 5 citations · Cited by this paper
  31. Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer · Kathryn Capasso · 2024 · 5 citations · Cited by this paper
  32. Comparing [18F]FDG–positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial · Juan Jose Garcia · 2025 · 4 citations · Cited by this paper
  33. Axillary Surgery in Breast Cancer: Evidence-Based De-escalation Across Upfront and Post-Neoadjuvant Settings · Woong Ki Park · 2025 · 3 citations · Cited by this paper
  34. 18F-FDG PET/CT for prediction of response in breast cancer · Mariza Vorster · 2026 · 3 citations · Cited by this paper
  35. [68Ga]Ga-labeled fibroblast activation protein inhibitor PET/CT for monitoring neoadjuvant chemotherapy responses in breast cancer subtypes · Ling Chen · 2026 · 2 citations · Cited by this paper
  36. Diagnostic Performance of (68)Ga-FAPI PET/CT Versus (18)F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer. · Siji Zhu · 2025 · 1 citation · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper

Source: OpenAlex (CC0)